Cargando…

Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab

The objective of the study was to evaluate whether Point-of-Care (POC) assays are equivalent to ELISAs for measuring residual trough levels of adalimumab (ADA) in a cohort of Inflammatory Bowel Disease (IBD) patients. ADA trough levels obtained by POC assays were used to optimize patients in daily c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cherry, Mohamad, Dutzer, Dominique, Nasser, Yara, Berger, Anne-Emmanuelle, Roblin, Xavier, Paul, Stephane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565289/ https://www.ncbi.nlm.nih.gov/pubmed/32854232 http://dx.doi.org/10.3390/jcm9092739

Ejemplares similares

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
por: Berger, Anne Emmanuelle, et al.
Publicado: (2022)

Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
por: Noor, Nurulamin M, et al.
Publicado: (2021)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)

Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer
por: Lavelle, Aonghus, et al.
Publicado: (2022)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

Proactive condition monitoring of low-speed machines
por: Stamboliska, Zhaklina, et al.
Publicado: (2015)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

A practical guide to thiopurine prescribing and monitoring in IBD
por: Warner, Ben, et al.
Publicado: (2018)

The Association of Childhood Fitness to Proactive and Reactive Action Monitoring
por: Kamijo, Keita, et al.
Publicado: (2016)

Encouraging performance monitoring promotes proactive control in children
por: Hadley, Lauren V., et al.
Publicado: (2019)

Accuracy of the new rapid test for monitoring adalimumab levels
por: Rocha, Cátia, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021)

Gut Serpinome: Emerging Evidence in IBD
por: Mkaouar, Héla, et al.
Publicado: (2021)

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
por: Sirmai, Laura, et al.
Publicado: (2022)

Proactive control of proactive interference using the method of loci
por: Bass, Willa S., et al.
Publicado: (2014)

Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment?
por: van Wassenaer, Elsa A., et al.
Publicado: (2022)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Proactively Monitoring Departmental Clinical IT Systems with an Open Source Availability System
por: Toland, C., et al.
Publicado: (2007)

Similar proactive effect monitoring in free and forced choice action modes
por: Pfeuffer, Christina U., et al.
Publicado: (2022)

IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False?
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2020)

IBD Monitor: Romanian National Mobile Application for Inflammatory Bowel Disease Personalized Treatment and Monitoring
por: Oancea, Carmen-Nicoleta, et al.
Publicado: (2022)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Do you feel like being proactive today? Trait-proactivity moderates affective causes and consequences of proactive behavior
por: Wolsink, Inge, et al.
Publicado: (2019)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Congenital toxoplasmosis after adalimumab treatment before pregnancy
por: Krull, Eloïse, et al.
Publicado: (2021)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

The Impact of Leader Proactivity on Follower Proactivity: A Chain Mediation Model
por: Zhang, Kaixin, et al.
Publicado: (2022)

Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants
por: Vogrig, Manon, et al.
Publicado: (2022)

Dissociation in reactive and proactive inhibitory control in Myoclonus dystonia
por: Atkinson-Clement, Cyril, et al.
Publicado: (2020)

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
por: Paramarta, Jacqueline E, et al.
Publicado: (2014)

Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab
por: Alahmari, Hana S., et al.
Publicado: (2019)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Zebrafish model for IBD
Publicado: (2011)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Proactive Risk Management
por: Smith, Preston, et al.
Publicado: (2020)

ProActive Selling
por: Miller, William
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_givd252g88qvir1t6fec44su5j